相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration
Henrik Agerso et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
J. M. Sommer et al.
HAEMOPHILIA (2014)
Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A
J-M. Gu et al.
HAEMOPHILIA (2014)
Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
S. Zollner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
A. Muto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
I. A. Ivens et al.
HAEMOPHILIA (2013)
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo
L. Tang et al.
HAEMOPHILIA (2013)
Liver as a target for oligonucleotide therapeutics
Alfica Sehgal et al.
JOURNAL OF HEPATOLOGY (2013)
Direct inhibition of factor VIIa by TFPI and TFPI constructs
S. Peraramelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study
P. Hilliard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA
A. Tiede et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Future of coagulation factor replacement therapy
F. Peyvandi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
Hubert J. Metzner et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood
Sabine Knappe et al.
THROMBOSIS AND HAEMOSTASIS (2013)
PROLONG-9FP clinical development program - phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)
Elena Santagostino
THROMBOSIS RESEARCH (2013)
Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII
Stefan Schulte
THROMBOSIS RESEARCH (2013)
Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
Christoph Kannicht et al.
THROMBOSIS RESEARCH (2013)
Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
Sabine B. Zollner et al.
THROMBOSIS RESEARCH (2013)
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
Amy D. Shapiro et al.
BLOOD (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
Elena Santagostino et al.
BLOOD (2012)
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
Ida Hilden et al.
BLOOD (2012)
Certolizumab pegol for the treatment of rheumatoid arthritis
Sarah Horton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
U. Martinowitz et al.
HAEMOPHILIA (2012)
Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada
J. Kraft et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
M. E. Gorczyca et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII
Helena Sandberg et al.
THROMBOSIS RESEARCH (2012)
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier et al.
BLOOD (2011)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
International comparative field study of N8 evaluating factor VIII assay performance
D. Viuff et al.
HAEMOPHILIA (2011)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
FDA-approved poly(ethylene glycol)-protein conjugate drugs
Steevens N. S. Alconcel et al.
POLYMER CHEMISTRY (2011)
Haemophilia B: impact on patients and economic burden of disease
Adam Gater et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Prolonged activity of factor IX as a monomeric Fc fusion protein
Robert T. Peters et al.
BLOOD (2010)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Baisong Mei et al.
BLOOD (2010)
Improvements in factor concentrates
David Lillicrap
CURRENT OPINION IN HEMATOLOGY (2010)
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Chichi Huang
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
Srinivasa Prasad et al.
BLOOD (2008)
Crystal structure of human factor VIII: Implications for the formation of the factor IXa-factor VIIIa complex
Jacky Chi Ki Ngo et al.
STRUCTURE (2008)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
B. A. Konkle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV
Sarah C. Darby et al.
BLOOD (2007)
Reformulated BeneFix®:: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B
T. Lambert et al.
HAEMOPHILIA (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study
BM Feldman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs
M. Hoffman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Haemophilia B: Christmas disease
P Giangrande
EXPERT OPINION ON PHARMACOTHERAPY (2005)
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
J Ahnström et al.
HAEMOPHILIA (2004)
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
P Caliceti et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective
S Björkman
HAEMOPHILIA (2003)
Comparing outcomes of different treatment regimens for severe haemophilia
HM Van den Berg et al.
HAEMOPHILIA (2003)
Prophylaxis in factor IX deficiency product and patient variation
CT Kisker et al.
HAEMOPHILIA (2003)
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
T Gui et al.
BLOOD (2002)
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
DA Roth et al.
BLOOD (2001)
Barriers to compliance with prophylaxis therapy in haemophilia
MR Hacker et al.
HAEMOPHILIA (2001)
分享论文
